Abstract
5-Fluorouracil (FUra) has been the drug of choice in the treatment of colorectal cancers (1,2), and it is widely utilized in a variety of other malignancies (3). FUra exerts its antiproliferative effect following metabolic activation to various nucleotides (Chart 1). 5-Fluorouridine triphosphate (FUTP), due to its resemblance with uridine triphosphate (UTP), is incorporated into RNA (4–7); the consequence of this incorporation is the production of fraudulent mRNA, rRNA and tRNA which can ultimately cause cell death. The other proposed mechanism for FUra cytotoxicity is the inhibition of thymidylate synthetase (dTMP-S) by 5-fluorodeoxyuridine monophosphate (FdUMP) (8–11), leading to decreased thymidine triphosphate (dTTP) pools and to inhibition of DNA synthesis. The biochemical mechanism by which FdUMP binds to the dTMP-S involves a cofactor, N5,10methylene tetrahydrofolic acid (N5,10CH2FH4). Santi et al. have calculated that the dissociation constant (Kd) of the ternary complex FdUMP-dTMP-SN5,10CH2FH4, is of the order of 5×10-11M. In absence of the reduced folate cofactor, FdUMP binding to dTMP-S is relatively weak, with a Kd of about 10-5M (9). An additional proposed mechanism of cytotoxicity of FUra is its incorporation into DNA (12–15). To date, little is known about the biological significance of this finding.
Keywords
- Maximally Tolerate Dose
- Advanced Colorectal Cancer
- Roswell Park Memorial Institute
- Bone Marrow Toxicity
- Metabolic Modulation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Carter S.K., Large bowel cancer-the current status of treatment. J. Natl. Cancer Inst.56: 3–10, 1976.
Levin P., Mittelman A., Douglass H., Engstrom P., Klaassen D., Survival and response rate to chemotherapy for advanced colorectal adenocarcinoma:an Eastern Cooperative Oncology Group report. Cancer(Phila.) 46: 1536–1543, 1980.
Cancer—Principles and practice of oncology. De Vita V.T. Jr., Hellman S., Rosenberg A. editors, J.B. Lippincott Co., Philadelphia 1982.
Mandel H.G. The incorporation of 5-fluorouracil in RNA and its molecular consequences. Prog. Mol. Subcell. Biol.1: 82–135, 1969.
Glazer R.I., Peale A.L. The effect of 5-fluorouracil on the synthesis of nuclear RNA in L1210 cells in vitro. Mol. Pharmacol.16: 270–277, 1979.
Kufe S.W., Major P.P. 5-Fluorouracil incorporation into human breast carcinoma DNA correlates with cytotoxicity. J. Biol. Chem.256: 9802–9805, 1981.
Glazer R.I., Lloyd L.S. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol. Pharmacol.21: 468–473, 1982.
Hartman K.U., Heidelberg C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J. Biol. Chem.236: 3006–3013, 1961.
Santi D.V., McHenry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridilate. Biochemistry13: 471–480, 1974.
Danenberg P.V., Locksin A. Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase. Pharmacol. Ther.13: 69–90, 1981.
Houghton J.A., Maroda S.J., Phillips J.D., Houghton P.J. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res. 41: 144–149, 1981.
Major P.P., Egan E., Herrick D., Kufe D.F. 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res. 42: 3005–3009, 1982.
Schuetz J.D., Wallace H.J., Diasio R.B. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res. 44: 1358–1363, 1984.
Sawyer R.C., Stolfi R.L., Martin D.S., Spiegelman S. Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo. Cancer Res. 44: 1847–1851, 1984.
Lonn U., Lonn S. Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res. 44: 3414–3418, 1984.
Bloch A. Metabolic Conditioning and Metabolic Actuation: experimental approaches to cancer chemotherapy involving combinations of metabolites and antimetabolites. Cancer Chemother. Rep.58: 471–477, 1974.
Martin D.S., Stolfi R.L., Spiegel man S. Striking augmentation of the in vivoanticancer activity of 5-fluorouracil by combination with pyrimidine nucleosides: an RNA effect. Proc. Am. Assoc. Cancer Res.29: 221, 1978.
Nayak R., Martin D.S., Stolfi R.L., Furth J., Spiegel man S. Pyrimidine nucleosides enhance the anticancer activity of 5-fluorouracil and augment its incorporation into nuclear RNA. Proc. Am. Assoc. Cancer Res.19: 1963, 1978.
Martin D.S., Stolfi R.L., Sawyer R.C., Nayak R., Spiegelman S., Young C.W., Woodcock T. An overview of thymidine. Cancer(Phila.) 45: 1117–1128, 1980.
Evans R.M., Laskin J.D., Hakala M.T. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41: 3288–3295, 1981.
Yin M-B., Zakrzewski S.F., Hakala M.T. Relationship of cellular folate cofactor pools to activity of 5-fluorouracil. Mol. Pharmacol.23: 190–197, 1983.
Danhauser L.L., Rustum Y.M. A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combination. J. Lab. Clin. Med.93: 1047–1053, 1979.
Au J.L-S., Rustum Y.M., Ledesma E.J., Mittelman A., Creaven P.J., Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res. 42: 2930–2937, 1982.
Sternberg A., Petrelli N.J., Au J., Rustum Y., Mittelman A., Creaven P., A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma. Cancer Chemother. Pharmacol.13: 218–222, 1984.
Madajewicz S., Petrelli N., Rustum Y., Campbell J. Herrera L., Mittelman A., Perry A., Creaven P.J. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 44: 4667–4669, 1984.
Danhauser L.L., Rustum Y.M. Chemotherapeutic efficacy of 5-fluorouracil with concurrent thymidine infusion against transplantable colon tumor in rodents. Cancer Drug Delivery1 (4): 269–282, 1984.
Rustum Y.M. High pressure liquid chromatography. I. Quantitative separation of purine and pyrimidine nucleosides and bases. Anal. Biochem.90: 289–299, 1978.
Trave F., Rustum Y.M., Mazzoni A., Petrelli N., Madajewicz S., Mittelman A., Creaven P. Possible effect of high dose 5-formyltetrahydrofolic acid on the pharmacokinetics of 5-fluorouracil in patients with colorectal carcinoma. Proc. Am. Soc. Clin. Oncol.4: 30, 1985.
Straw J.A., Szapary D., Wynn W.T. Pharmacokinetic of the diastereo-isomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res. 44: 3114–3119, 1984.
Moertel C.G., Schut A.J., Reitemeier R.J., Hahn R.G. A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res. 32: 2717–2719, 1972.
Seifert P., Baker L.H., Reed M.L., Vaitkevicius V.K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer36: 123–128, 1975.
Fraile R.J., Baker L.H., Buroker T.R., Horwitz J., Vaitkevicius V.K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 42: 2223–2228, 1980.
Machover D., Schwarzenberg L., Goldschmidt E., Tourani J.M., Michalski B.Hayat M., Dorval T., Misset J.L., Jasmin C., Maral R., Mathe’ G. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high dose folinic acid: a pilot study. Cancer Treat. Rep.66: 1803–1807, 1982.
Woodcock T.M., Martin D.S., Damin L.A.M., Kerneny N.E., Yuong C.W. Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer45: 1135–1143, 1980.
Laskin J.D., Evans R.M., Slocum H.K., Burke D., Hakala M.T. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 39: 383–390, 1979.
Evans R.M., Laskin J.D., Hakala M.D. Assessment of growth limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 40: 4113–4122, 1980.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Trave, F., Rustum, Y.M. (1986). 5-Fluorouracil Plus Thymidine or Leucovorin by Continuous I.V. Infusion in the Treatment of Advanced Colorectal Carcinoma. In: Rosenthal, C.J., Rotman, M. (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2197-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2197-2_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9291-3
Online ISBN: 978-1-4613-2197-2
eBook Packages: Springer Book Archive